NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) Director Lynn Tetrault sold 5,307 shares of NeoGenomics stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total transaction of $59,916.03. Following the completion of the sale, the director owned 91,422 shares of the company’s stock, valued at approximately $1,032,154.38. The trade was a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
NeoGenomics Stock Down 2.8%
NASDAQ NEO opened at $11.15 on Friday. The company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41. NeoGenomics, Inc. has a 1-year low of $4.72 and a 1-year high of $13.74. The company has a 50 day moving average of $9.08 and a 200-day moving average of $10.32. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -14.48 and a beta of 1.82.
NeoGenomics (NASDAQ:NEO – Get Free Report) last released its quarterly earnings results on Tuesday, April 28th. The medical research company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. The company had revenue of $186.67 million during the quarter, compared to the consensus estimate of $184.54 million. NeoGenomics had a negative net margin of 13.30% and a negative return on equity of 2.80%. The firm’s revenue was up 11.3% on a year-over-year basis. On average, equities research analysts expect that NeoGenomics, Inc. will post -0.15 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on NEO
Institutional Trading of NeoGenomics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. First Light Asset Management LLC grew its stake in shares of NeoGenomics by 1.1% during the fourth quarter. First Light Asset Management LLC now owns 10,035,063 shares of the medical research company’s stock worth $118,012,000 after buying an additional 107,794 shares during the last quarter. Greenhouse Funds LLLP grew its stake in shares of NeoGenomics by 10.6% during the third quarter. Greenhouse Funds LLLP now owns 8,220,657 shares of the medical research company’s stock worth $63,463,000 after buying an additional 789,510 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of NeoGenomics during the first quarter worth $45,725,000. Geode Capital Management LLC grew its stake in shares of NeoGenomics by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 3,176,644 shares of the medical research company’s stock worth $37,364,000 after buying an additional 44,733 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of NeoGenomics by 9.2% during the first quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after buying an additional 225,588 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.
About NeoGenomics
NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.
The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.
Featured Stories
- Five stocks we like better than NeoGenomics
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.
